Third Quarter Report 2006
Oslo, Norway, October 27th, 2006 Highlights: · GE Healthcare exercised an option to market and distribute Hexvix® in the US. This triggered a milestone payment of EUR 9 million to be booked in fourth quarter. · Hexvix launched in Germany by GE Healthcare. · Metvix® launched in Brazil and Metvixia® approved for AK, BCC and Bowen's in France. · First Phase II study in acne completed. · First clinical study for treatment of Cervix cancer started. · Sales revenues in third quarter amounted to NOK 14.6 million (7.3), an increase of 99%. · Net loss third quarter